Expanded access policy

Bavarian Nordic is committed to developing new vaccines for the prevention of various serious and life-threatening diseases. We believe that the best way for patients to access our investigational products is through clinical trials designed to evaluate safety and efficacy. Bavarian Nordic strives to partner with world-class medical experts in our respective fields of clinical trial investigation. It is through these trials that patients receive current standard of care as well as the possibility of access to our experimental vaccines.

Another method of patient access to investigational products for serious or life-threatening diseases when there are no other treatment options available is through expanded access programs, also referred to as compassionate use programs.

Exceptionally and if vaccines are still available for use, Bavarian Nordic will evaluate and at its sole discretion decide on a case-by-case basis HCP requests for expanded access of its experimental vaccines.

For further questions about Bavarian Nordic’s expanded access policy, please contact us. We will respectfully acknowledge your request within 10 days of receipt.